ArticleCancer reports (Hoboken, N.J.)2025
A Case of Advanced Lung Adenocarcinoma Successfully Treated by Intratumoral Injection of Tirelizumab Under Tracheoscopy.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Endobronchial Intratumoral Immuno- and Gene Therapies in Lung Cancer: Mechanisms of Local Delivery, Systemic Immune Effects, and Global Feasibility.International journal of molecular sciences · 2026Review
- A Case of Advanced Lung Adenocarcinoma Successfully Treated by Intratumoral Injection of Tirelizumab Under Tracheoscopy.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionLung cancer is a leading cause of cancer-related deaths, with an annual mortality rate of nearly 1.8 million. Among its subtypes, lung adenocarcinoma is increasingly prevalent. Due to its often asymptomatic nature, most patients are diagnosed at advanced stages, missing the optimal window for surgery and resulting in a poor 5-year survival rate. CASE PRESENTATION: We present the case of an 83-year-old patient with stage IV lung adenocarcinoma treated with four cycles of intravenous Tirelizumab and two cycles of intratumoral Tirelizumab via tracheoscopy. The patient achieved partial clinical remission, with tumor lesions continuing to shrink upon follow-up by August 24, 2024. No treatment-related adverse reactions were observed, and the patient's immune function remained normal.
conclusionsThis case suggests that systemic intravenous Tirelizumab combined with tracheoscopic intratumoral injection may offer a safe and effective treatment strategy for lung adenocarcinoma, particularly for patients unsuitable for chemotherapy or surgery. However, further prospective studies and clinical trials are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.